Torres-Estrella Carlos U, Reyes-Montes María Del Rocío, Duarte-Escalante Esperanza, Sierra Martínez Mónica, Frías-De-León María Guadalupe, Acosta-Altamirano Gustavo
Hospital Regional de Alta Especialidad de Ixtapaluca, Ciudad de México PC 56530, Mexico.
Unidad Profesional Interdisciplinaria de Biotecnología, Instituto Politécnico Nacional (IPN), Ciudad de México PC 07340, Mexico.
Vaccines (Basel). 2022 Mar 10;10(3):414. doi: 10.3390/vaccines10030414.
As a result of the COVID-19 pandemic, various joint efforts have been made to support the creation of vaccines. Different projects have been under development, of which some are in the clinical evaluation stage and others in are in phase III with positive results. The aim of this paper was to describe the current situation of the development and production of vaccines available to the population to facilitate future research and continue developing and proposing ideas for the benefit of the population. So, we carried out a systematic review using databases such as PubMed, ScienceDirect, SciELO, and MEDLINE, including keywords such as "vaccines," "COVID-19," and "SARS-CoV-2". We reviewed the development and production of the anti-COVID vaccine and its different platforms, the background leading to the massive development of these substances, and the most basic immune aspects for a better understanding of their physiological activity and the immune response in those who receive the vaccine. We also analyzed immunization effects in populations with any medical or physiological conditions (such as immunosuppression, people with comorbidities, and pregnancy), as well as the response to immunization with heterologous vaccines and the hybrid immunity (the combination of natural immunity to SARS-CoV-2 with immunity generated by the vaccine). Likewise, we address the current situation in Mexico and its role in managing the vaccination process against SARS-CoV-2 at the national and international levels. There are still many clinical and molecular aspects to be described, such as the duration of active immunity and the development of immunological memory, to mention some of the most important ones. However, due to the short time since the global vaccination roll-out and that it has been progressive (not counting children and people with medical conditions), it is premature to say whether a second vaccination schedule will be necessary for the near future. Thus, it is essential to continue with health measures.
由于新冠疫情,各方共同努力支持疫苗研发。不同项目正在推进,其中一些处于临床评估阶段,另一些处于三期且取得了积极成果。本文旨在描述可供民众使用的疫苗研发和生产现状,以促进未来研究,并继续为民众的福祉提出新想法。为此,我们使用了PubMed、ScienceDirect、SciELO和MEDLINE等数据库进行系统综述,纳入了“疫苗”“新冠病毒病”和“严重急性呼吸综合征冠状病毒2”等关键词。我们回顾了新冠疫苗的研发和生产及其不同平台、促使这些物质大量研发的背景,以及最基本的免疫方面,以便更好地理解其生理活性和接种疫苗者的免疫反应。我们还分析了有任何医学或生理状况人群(如免疫抑制、患有合并症者和孕妇)的免疫效果,以及对异源疫苗免疫的反应和混合免疫(对严重急性呼吸综合征冠状病毒2的天然免疫与疫苗产生的免疫相结合)。同样,我们探讨了墨西哥的现状及其在国家和国际层面管理针对严重急性呼吸综合征冠状病毒2的疫苗接种过程中的作用。仍有许多临床和分子方面有待描述,例如主动免疫的持续时间和免疫记忆的形成,仅列举一些最重要的方面。然而,由于全球疫苗接种开始时间较短且呈渐进式(不包括儿童和有医疗状况的人群),现在说近期是否需要第二轮接种计划还为时过早。因此,继续采取卫生措施至关重要。